Peptide News Digest

#Pluvicto

3 stories

Regulatory · View digest

ITM Isotope Technologies Munich SE Received a Complete Response Letter (CRL) From the US Food and Drug Administration on August 7, 2026 for 177Lu-Edotreotide (ITM-11), a Somatostatin Analog Radioligand Peptide Therapeutic Under Investigation for Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs); The CRL Cited Chemistry, Manufacturing, and Controls (CMC) and Third-Party Commercial Manufacturing Facility Items to Address Before Resubmission, but the FDA Did Not Identify Any Concerns Regarding the Clinical Data Package, Nonclinical Data, or Safety Profile of ITM-11; The Company Intends to Resubmit to Complete the NDA Review and Continues to Pursue Approval Following the COMPETE Trial (NCT03049189) Phase 3 Comparison of 177Lu-Edotreotide Versus Everolimus in Inoperable Progressive Grade 1 or Grade 2 GEP-NETs

ITM Isotope Technologies Munich SE received a Complete Response Letter (CRL) from the US FDA on August 7, 2026, disclosed August 10-11, for 177Lu-edotreotide (ITM-11), a somatostatin analog radioligand peptide therapeutic under investigation for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The CRL cited chemistry, manufacturing, and controls (CMC) and third-party commercial manufacturing facility items that must be addressed before the application can be approved. Notably, the FDA did not identify any concerns regarding the clinical data package, nonclinical data, or safety profile of ITM-11. The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide compared to everolimus (an oral mTOR inhibitor targeted molecular therapy) in patients with inoperable, progressive Grade 1 or Grade 2 GEP-NETs. ITM-11 is a peptide radioligand therapy: a somatostatin receptor 2 (SSTR2)-targeting peptide chelated to the beta-emitting radionuclide lutetium-177 to deliver targeted radiation to SSTR2-expressing neuroendocrine tumor cells. The category is anchored commercially by Novartis's Lutathera (177Lu-dotatate) and Pluvicto (177Lu-vipivotide tetraxetan, PSMA-targeting for prostate cancer). ITM intends to resubmit and complete the NDA review process. The manufacturing-focused CRL is a substantially better outcome than a clinical-data CRL: resolution timelines for CMC-only CRLs typically run 4-8 months versus 12+ months for data-driven CRLs, and the fundamental commercial thesis remains intact.

Research · View digest

Nature Publishes Landmark Anticancer Peptide Study on aMPC16-CA50, a Synthetic Acid-Responsive Membranolytic Peptide That Induces Immunogenic Membranolytic Cell Death (MCD) in Tumor Cells and Substantially Potentiates Immune Checkpoint Blockade Therapy in Preclinical Mouse Models; The Membranolytic Mechanism Differentiates aMPC16-CA50 From Both Traditional Chemotherapy (Which Typically Induces Apoptosis) and From Antibody-Drug Conjugates and CAR-T Cell Therapies, Extending the Anticancer-Peptide Research Trajectory That Has Moved Through Preclinical Validation Into Early Clinical Translation With Products Like Cybrexa's CBX-12 (26-Amino-Acid Peptide-Drug Conjugate) and Novartis's Pluvicto (Lutetium-177 Vipivotide Tetraxetan, PSMA-Targeting Radiopeptide)

Nature published a landmark anticancer peptide study on aMPC16-CA50, a synthetic acid-responsive membranolytic peptide that induces immunogenic membranolytic cell death (MCD) in tumor cells and substantially potentiates immune checkpoint blockade (anti-PD-1/PD-L1) therapy in preclinical mouse tumor models. The peptide is designed to respond to the acidic microenvironment of tumor tissue: at neutral pH the peptide remains inactive, but at the lower pH characteristic of tumor tissue (pH 6.0-6.5) the peptide undergoes conformational changes that allow it to insert into tumor cell membranes and induce membranolytic damage. The resulting cell death is immunogenic (releases damage-associated molecular patterns that alert the immune system) rather than apoptotic (which is typically immunologically silent), producing a mechanism that synergizes with checkpoint inhibitor therapy. The membranolytic mechanism differentiates aMPC16-CA50 from both traditional chemotherapy (which typically induces apoptosis) and from antibody-drug conjugates and CAR-T cell therapies. The paper extends the anticancer-peptide research trajectory that has moved through preclinical validation into early clinical translation with products including Cybrexa Therapeutics's CBX-12 (26-amino-acid peptide-drug conjugate for platinum-resistant ovarian cancer, Phase 2 ongoing) and Novartis's Pluvicto (lutetium-177 vipivotide tetraxetan, PSMA-targeting radiopeptide approved for metastatic prostate cancer).

Industry · View digest

Peptide Drug Conjugate Market Projected to Exceed $1.5B by 2031 with 50+ Conjugates in Trials

A new market landscape report published April 21 projects the global peptide drug conjugate market will exceed $1.5 billion by 2031, with >14% CAGR and coverage of more than 50 peptide conjugates currently in clinical development. Commercial PDC benchmarks include Novartis's Lutathera and Pluvicto and Bicycle Therapeutics' nuzefatide pevedotin, with earlier-stage pipelines from Zymeworks, Bicycle, PeptiDream, and others.